NPA In Coalition Pushing For Pandemic Tax Credit In Next US Economic Stimulus Package

NPA part of broad coalition of industry groups asking Congress to provide a tax credit in the next stimulus package to help businesses absorb cost related to COVID-19 safety precautions. NPA notes in a 6 August release that those costs will amount to about $13,595 annually for natural products marketers.

Notebook with tax credit sign on a table. Business concept.

The Natural Products Association is part of a coalition asking Congress to include in the next pandemic stimulus package a tax credit to help businesses pay for safety and testing precautions that NPA members say will cost on average $13,595 annually.

“As Americans have turned to nutritional supplements to support their health and immune systems in the crisis, natural products businesses have truly been a lifeline

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

More from Policy & Regulation

US Tariffs Pose ‘Existential Threat’ To EU Medical Devices Industry

 
• By 

AESGP, MedTech Europe and other associations representing medtech companies including manufacturers of self-care devices call for such products to be included in European Commission proposals for “zero-for-zero” trade in industrial goods between Europe and the US.

Stakeholders Hope US FDA’s Proposed Animal Test Phase-Out For Drugs Will Extend To OTCs, Cosmetics

 
• By 

The US Food and Drug Administration has released a roadmap to adopt new approach methodologies in lieu of animal testing for monoclonal antibody therapies and other drugs, which may include OTC drugs though the proposal does not specifically include cosmetics.

Melatonin And Buccal Acyclovir On German Switch Committee Agenda

 
• By 

An application for melatonin as an OTC medicine is on the agenda for the next German switch committee meeting, despite the hormone being widely available in food supplements. Acyclovir as a buccal tablet and second-generation antihistamine rupatadine are also up for discussion.